Skip Navigation

infoSIDA logo

 
Home > Drugs > Apricitabine

Apricitabine
  Audio
Drug Class: Nucleoside Reverse Transcriptase Inhibitors
Apricitabine, also known as AVX754 or SPD754, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs work by blocking reverse transcriptase, a protein that HIV needs to make more copies of itself.

HIV/AIDS-Related Uses
Apricitabine is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection in treatment-experienced patients and has been granted fast-track status by the FDA. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration
Apricitabine is taken by mouth in clinical trials.

Recommended Daily Dose
Daily doses of 400 to 1,600 mg have been studied in early trials. Twice-daily dosing has been selected for further study.

Contraindications
Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects
Along with its desired effects, apricitabine may cause some unwanted effects. Further study is needed to identify these side effects.

Drug and Food Interactions
A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials
Click here to search ClinicalTrials.gov for trials that use Apricitabine.

Manufacturer Information
Apricitabine
  Avexa Limited
  576 Swan Street
  Richmond Victoria,  Australia
  61-3-9208-4300
    
Updated March 13, 2007